ProCE Banner Activity

Smarter. Stronger. Together. Optimizing MDS Care and Addressing Health Disparities Through Education of Providers, Patients, and Caregivers

Slideset

Slides from Amer Zeidan, MBBS, highlighting some of the most important developments in optimizing the management of myelodysplastic syndromes, including patient survey results, clinical trial findings and their implications for clinical practice

Released: November 22, 2023

Share

Faculty

Amer Zeidan

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

Provided by Clinical Care Options LLC, in partnership with The Myelodysplastic Syndromes Foundation, Inc.

ProCE Banner

Supporters

Supported by an educational grant from AbbVie Inc., Geron and Karyopharm Therapeutics.

AbbVie Inc.

Geron

Karyopharm Therapeutics

Partners

MDS Foundation

ProCE Banner

Disclosure

Primary Author

Amer Zeidan, MBBS, MHS

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Amer Zeidan, MBBS, MHS: researcher: AbbVie, Amgen, Astex, Bristol Myers Squibb, Celgene, Geron, Kura, Novartis, Otsuka, Shattuck Labs, Syros; consultant/advisor/speaker: AbbVie, Agios, Akeso Pharma, ALX Oncology, Amgen, Astellas, BeiGene, BioCryst, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Chiesi, Daiichi Sankyo, Epizyme, Faron, Genentech, Geron, Gilead, Glycomimetics, Hikma, Janssen, Karyopharm, Keros, Kura, Kyowa Kirin, Lava Therapeutics, Mendus, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Schrodinger, Servier, Sumitomo, Syndax, Syros, Taiho, Takeda, Treadwell, Vincerx, Zentalis.